New Survey Highlights Impact of Common,(1) But Under-Recognized Condition on Stroke Survivors and Their Caregivers

 New Survey Highlights Impact of Common,(1) But Under-Recognized Condition on
                    Stroke Survivors and Their Caregivers

Spasticity Ranked Among Top Three Post-Stroke Symptoms Impacting Patients

PR Newswire

IRVINE, Calif., Oct. 29, 2013

IRVINE, Calif., Oct. 29, 2013 /PRNewswire/ -- Seventy percent of stroke
survivors living with spasticity and their caregivers rank the debilitating
condition as one of the top three symptoms impacting their life post-stroke,
according to a recent survey conducted by Allergan, Inc. and National Stroke
Association. Spasticity, which causes muscles to contract and spasm, causing
stiffness and pain ranks second only to paralysis in its impact, yet close to
50 percent of stroke survivors and their caregivers are unaware of the
available treatment options.

Stroke is the leading cause of serious, long-term disability in the United
States.^2 Today, there are approximately seven million stroke survivors in
this country.^3According to a survey of stroke survivors and their primary
caregivers, approximately 60 percent (n=504) of stroke survivors live with
spasticity.^4 Many may have upper limb spasticity.^5Upper limb spasticity,
which affects the elbow, wrist and fingers, can present as a bent wrist with
fingers pointing downward, a fist that stays clenched or a flexed elbow that
stays twisted against the chest.

"Spasticity significantly impacts the daily routines of both stroke survivors
and their caregivers," says Jim Baranski, Chief Executive Officer, National
Stroke Association. "People living with upper limb spasticity often are not
able to do the simplest of tasks like getting dressed, hand washing, or even
eating. They grow dependent on their loved ones for help with these basic
tasks. It's important for stroke survivors and their caregivers to know that
spasticity is a very real medical condition and they should talk with their
physician to get help."

Spasticity can occur weeks, months or even years after a stroke,^6 possibly
after a patient has stopped seeing a physician for his/her follow-up care.
Spasticity continues to be under-recognized and inadequately managed.^7

Although more than 95 percent of the physicians surveyed believe spasticity
has a moderate to severe impact on their patients' lives, 31 percent of
neurologists and 27 percent of primary care physicians focus on preventing a
secondary stroke, and 22 percent of neurologists and 26 percent of primary
care givers focus on managing acute needs when treating stroke survivors.
Physical therapists and physiatrists* (or Physical Medicine & Rehabilitation
Specialists/PM&Rs), on the other hand, are much more focused on helping manage
the after-effects of a stroke with 22 percent of PM&Rs and 38 percent of
physiotherapists reporting that their focus in the first six months of a
stroke patient's follow-up care is on understanding and discussing physical
complications like spasticity.

"It is critical for physicians to address spasticity with their post-stroke
patients at the onset of, and throughout, their follow-up care," said Dr.
Elliot J. Roth, Medical Director of the Patient Recovery Unit and Attending
Physician, Rehabilitation Institute of Chicago; Professor & Chairman, PM&R,
Northwestern University Feinberg School of Medicine. "Spasticity is a
disabling condition, but, often times, patients are either uncomfortable or
too overwhelmed to discuss it with their physician. The focus after someone
has experienced a stroke is so commonly on preventing a second stroke, that
rehabilitation goals are covered in broad terms. This can leave patients and
their caregivers feeling unprepared for a larger discussion about the
post-stroke symptoms they may be experiencing, including spasticity. It's
critical that patients and caregivers understand that even if a person has
been experiencing spasticity for years, in many cases there are ways to help
manage the condition."

For more information about spasticity, including an interactive discussion
guide to help patients and caregivers facilitate a conversation with their
healthcare professional, please visit

About the Survey
Two parallel surveys were conducted to better understand perceptions and
experiences relating to spasticity amongst patients, caregivers and healthcare

  oThe Spasticity Patient and Caregiver Survey was conducted by M3 Global, a
    global insight and strategy firm, in September 2013 among 100 stroke
    survivors affected by spasticity and 200 caregivers of patients who have
    had a stroke, using an email invitation and an online survey sent by M3.
  oThe Spasticity Healthcare Professional Survey was also conducted by M3
    Global in September 2013 among 780 healthcare professionals, including 300
    neurologists, 220 primary care physicians, 160 physical therapy
    specialists, and 100 physiatrists, using an email invitation and online
    survey sent by M3.

About National Stroke Association
National Stroke Association is a non-profit organization whose mission is to
reduce the incidence and impact of stroke by developing compelling education
and programs focused on prevention, treatment, rehabilitation and support for
all impacted by stroke. To learn more, visit

About Allergan, Inc.
Allergan is a multi-specialty healthcare company established more than 60
years ago with a commitment to uncover the best of science and develop and
deliver innovative and meaningful treatments to help people reach their life's
potential. Today, we have approximately 11,200 highly dedicated and talented
employees, global marketing and sales capabilities with a presence in more
than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals,
biologics, medical devices and over-the-counter consumer products, and
state-of-the-art resources in R&D, manufacturing and safety surveillance that
help millions of patients see more clearly, move more freely and express
themselves more fully. From our beginnings as an eye care company to our focus
today on several medical specialties, including eye care, neurosciences,
medical aesthetics, medical dermatology, breast aesthetics, obesity
intervention and urologics, Allergan is proud to celebrate more than 60 years
of medical advances and proud to support the patients and physicians who rely
on our products and the employees and communities in which we live and work.
For more information regarding Allergan, go

Forward-Looking Statements
This press release contains "forward-looking statements" including but not
limited to the statements by Mr. Baranski and Dr. Roth, as well as other
statements regarding the potential treatment of post-stroke spasticity
patients. These statements are based on current expectations of future events.
If underlying assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could vary materially from Allergan's expectations
and projections. Risks and uncertainties include, among other things, general
industry and medical device market conditions; challenges related to achieving
regulatory approval from the FDA on a timely and cost-efficient manner;
technological advances and patents attained by competitors; inconsistency of
treatment results among patients; potential difficulties in manufacturing;
challenges related to new product marketing, such as the unpredictability or
market acceptance for new products and/or the acceptance of new indications
for such products; and governmental laws and regulations affecting domestic
and foreign operations. Allergan expressly disclaims any intent or obligation
to update these forward-looking statements except as required by law.
Additional information concerning these and other risks can be found in press
releases issued by Allergan, as well as Allergan's public periodic filings
with the U.S. Securities and Exchange Commission, including the discussion
under the heading "Risk Factors" in Allergan's most recent Annual Report on
Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Copies of
Allergan's press releases and additional information about Allergan are
available at or you can contact the Allergan Investor
Relations Department by calling


^1Francisco GE, McGuire JR. Poststroke Spasticity Management. Stroke.
^2The Internet Stroke Center. Stroke Statistics. Available at Last
accessed October 1, 2013.
^3American Heart Association. Executive Summary: Heart Disease and Stroke
Statistics--2012 Update: A Report From the American Heart Association.
Circulation. 2012;125:188-197
^4National Stroke Association. Stroke Perceptions Study. Available at
Last accessed October 22, 2013.
^5Data on file, Allergan, Inc. Global Safety and Epidemiology: Spasticity
and comorbidity following five disorders: stroke, multiple sclerosis, spinal
cord injury, traumatic brain injury, and cerebral palsy in adults, 2009.
^6Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early
development of spasticity following stroke: a prospective, observational
trial. J Neurol. 2010;257:1067-1072.
^7National Stroke Association (2006). New Survey Emphasizes Need for More,
Better Care After Stroke (press release). Available at
Last accessed October 2, 2013.

SOURCE Allergan, Inc.

Contact: Naziah Lasi-Tejani, 714-246-3843; 949-413-9927; (Allergan); or Emily Boucher, 215-928-2371; (Tonic Life Communications)
Press spacebar to pause and continue. Press esc to stop.